Stromal control of oncogenic traits expressed in response to the overexpression of GLI2, a pleiotropic oncogene

A. M. Snijders, B. Huey, S. T. Connelly, R. Roy, R. C K Jordan, Brian Schmidt, Donna Albertson

Research output: Contribution to journalArticle

Abstract

Hedgehog signaling is often activated in tumors, yet it remains unclear how GLI2, a transcription factor activated by this pathway, acts as an oncogene. We show that GLI2 is a pleiotropic oncogene. The overexpression induces genomic instability and blocks differentiation, likely mediated in part by enhanced expression of the stem cell gene SOX2. GLI2 also induces transforming growth factor (TGF)B1-dependent transdifferentiation of foreskin and tongue, but not gingival fibroblasts into myofibroblasts, creating an environment permissive for invasion by keratinocytes, which are in various stages of differentiation having downregulated GLI2. Thus, upregulated GLI2 expression is sufficient to induce a number of the acquired characteristics of tumor cells; however, the stroma, in a tissue-specific manner, determines whether certain GLI2 oncogenic traits are expressed.

Original languageEnglish (US)
Pages (from-to)625-637
Number of pages13
JournalOncogene
Volume28
Issue number5
DOIs
StatePublished - Feb 5 2009

Fingerprint

Oncogenes
Foreskin
Myofibroblasts
Genomic Instability
Transforming Growth Factors
Keratinocytes
Tongue
Neoplasms
Transcription Factors
Stem Cells
Down-Regulation
Fibroblasts
Genes

Keywords

  • GLI2
  • Invasion
  • Organotypic culture
  • Transdifferentiation

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Stromal control of oncogenic traits expressed in response to the overexpression of GLI2, a pleiotropic oncogene. / Snijders, A. M.; Huey, B.; Connelly, S. T.; Roy, R.; Jordan, R. C K; Schmidt, Brian; Albertson, Donna.

In: Oncogene, Vol. 28, No. 5, 05.02.2009, p. 625-637.

Research output: Contribution to journalArticle

Snijders, A. M. ; Huey, B. ; Connelly, S. T. ; Roy, R. ; Jordan, R. C K ; Schmidt, Brian ; Albertson, Donna. / Stromal control of oncogenic traits expressed in response to the overexpression of GLI2, a pleiotropic oncogene. In: Oncogene. 2009 ; Vol. 28, No. 5. pp. 625-637.
@article{014e0fc845854066af9b5173f1b30f4b,
title = "Stromal control of oncogenic traits expressed in response to the overexpression of GLI2, a pleiotropic oncogene",
abstract = "Hedgehog signaling is often activated in tumors, yet it remains unclear how GLI2, a transcription factor activated by this pathway, acts as an oncogene. We show that GLI2 is a pleiotropic oncogene. The overexpression induces genomic instability and blocks differentiation, likely mediated in part by enhanced expression of the stem cell gene SOX2. GLI2 also induces transforming growth factor (TGF)B1-dependent transdifferentiation of foreskin and tongue, but not gingival fibroblasts into myofibroblasts, creating an environment permissive for invasion by keratinocytes, which are in various stages of differentiation having downregulated GLI2. Thus, upregulated GLI2 expression is sufficient to induce a number of the acquired characteristics of tumor cells; however, the stroma, in a tissue-specific manner, determines whether certain GLI2 oncogenic traits are expressed.",
keywords = "GLI2, Invasion, Organotypic culture, Transdifferentiation",
author = "Snijders, {A. M.} and B. Huey and Connelly, {S. T.} and R. Roy and Jordan, {R. C K} and Brian Schmidt and Donna Albertson",
year = "2009",
month = "2",
day = "5",
doi = "10.1038/onc.2008.421",
language = "English (US)",
volume = "28",
pages = "625--637",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Stromal control of oncogenic traits expressed in response to the overexpression of GLI2, a pleiotropic oncogene

AU - Snijders, A. M.

AU - Huey, B.

AU - Connelly, S. T.

AU - Roy, R.

AU - Jordan, R. C K

AU - Schmidt, Brian

AU - Albertson, Donna

PY - 2009/2/5

Y1 - 2009/2/5

N2 - Hedgehog signaling is often activated in tumors, yet it remains unclear how GLI2, a transcription factor activated by this pathway, acts as an oncogene. We show that GLI2 is a pleiotropic oncogene. The overexpression induces genomic instability and blocks differentiation, likely mediated in part by enhanced expression of the stem cell gene SOX2. GLI2 also induces transforming growth factor (TGF)B1-dependent transdifferentiation of foreskin and tongue, but not gingival fibroblasts into myofibroblasts, creating an environment permissive for invasion by keratinocytes, which are in various stages of differentiation having downregulated GLI2. Thus, upregulated GLI2 expression is sufficient to induce a number of the acquired characteristics of tumor cells; however, the stroma, in a tissue-specific manner, determines whether certain GLI2 oncogenic traits are expressed.

AB - Hedgehog signaling is often activated in tumors, yet it remains unclear how GLI2, a transcription factor activated by this pathway, acts as an oncogene. We show that GLI2 is a pleiotropic oncogene. The overexpression induces genomic instability and blocks differentiation, likely mediated in part by enhanced expression of the stem cell gene SOX2. GLI2 also induces transforming growth factor (TGF)B1-dependent transdifferentiation of foreskin and tongue, but not gingival fibroblasts into myofibroblasts, creating an environment permissive for invasion by keratinocytes, which are in various stages of differentiation having downregulated GLI2. Thus, upregulated GLI2 expression is sufficient to induce a number of the acquired characteristics of tumor cells; however, the stroma, in a tissue-specific manner, determines whether certain GLI2 oncogenic traits are expressed.

KW - GLI2

KW - Invasion

KW - Organotypic culture

KW - Transdifferentiation

UR - http://www.scopus.com/inward/record.url?scp=59649111693&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=59649111693&partnerID=8YFLogxK

U2 - 10.1038/onc.2008.421

DO - 10.1038/onc.2008.421

M3 - Article

VL - 28

SP - 625

EP - 637

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 5

ER -